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Conclusions: Our findings suggest that miR-34a is involved in
docetaxel resistance, which may act by targeting BCL2 and
cyclinD1.
doi:10.1016/j.ejcsup.2010.06.055
O-55 TRANSLATIONAL LANDSCAPE OF EPITHELIAL MESEN-
CHYMAL TRANSITION IN MOLECULAR CLASSES OF INVASIVE
BREAST CANCER
Mohammed A. Aleskandarany a, Andrew R. Green a, Emad A.
Rakha b, Des G. Poweb, Ian O. Ellis a,b. aDivision of Pathology,
University of Nottingham, UK. bDepartment of Pathology, Nottingham
University Hospitals, UK
Epithelial Mesenchymal Transition (EMT), as defined by loss of
epithelial characteristics and gaining a more mesenchymal-like
phenotype, has been largely reported in vivo. However, the actual
occurrence of events defining EMT is rarely fully observed in vivo.
We aimed to explore the translational landscapes of EMT in
breast cancer (BC) with relevance to potential triggering pathways
and BC molecular subtypes. Clustering analysis was performed
on a well-defined clinically annotated series of invasive non-lob-
ular BC (n = 431) prepared as tissue microarray (TMAs). A large
panel of biomarkers including cadherins, TGFb1, PIK3CA, pAkt,
cytokeratins, Erb-family members and hormone receptors, has
been studied. Differential expression of EMT markers was
observed between molecular BC subtypes (Luminal1 and 2,
HER2+, and basal-like (BLBC), where BLBC expressed lower E-
cad, higher P-cad, smooth muscle actin and PIK3CA, relative to
HER2+ BC that expressed highest levels of N-cad, TGFb1 and
PIK3CA. Within luminal tumours subdivisions, expression levels
of N-cad, TGFb1, pAkt and PIK3CA differed considerably. N-cad
contributed to cluster separation more than E-cad (F = 13.14 and
1.68, respectively). Moreover, E-cad/N-cad switch occurred more
frequently in BLBC and HER2+. Significant differences were
observed between these four clusters for breast cancer-specific
and disease-free survivals (p < 0.001).
BLBC and HER2+ BC preferentially displayed EMT/cadherin
switch than luminal BC, explaining their indigenous tendency
for progression. In addition, EMT/cadherin switch programs in
BC appear to occur synergistically with TGFb1 and PIK3/Akt path-
ways activation. These data explain, at translational level, the
varied clinical behaviour of BC molecular classes, thus could help
developing targeted therapies against EMT-associated pathways.
doi:10.1016/j.ejcsup.2010.06.056
O-56 HIGH EXPRESSION OF SPHINGOSINE 1-PHOSPHATE
RECEPTORS, S1P1 AND S1P3, SPHINGOSINE KINASE 1 AND ERK-
1/2 IS ASSOCIATED WITH DEVELOPMENT OF TAMOXIFEN
RESISTANCE IN ER POSITIVE BREAST CANCER PATIENTS
Carol Watson, Jaclyn S. Long, Clare Orange, Claire L. Tannahill,
Elizabeth Mallon, Liane M. McGlynn, Susan Pyne, Nigel J. Pyne,
Joanne Edwards. University of Glasgow, UK
Cell line studies demonstrate that sphingosine kinase 1 (SK1)
and extracellular signal regulated kinase 1/2 (ERK-1/2) interact in
an oestrogen receptor (ER) dependent manner to influence
breast cancer cell growth and migration. A cohort of 304 ER posi-
tive breast cancer patients, were utilised to investigate the prog-
nostic significance of SK1, sphingosine 1-phosphate receptors 1,
2 and 3 (S1P1, S1P2 an S1P3) and ERK-1/2 expression. Expression
levels of SK1, S1P1, S1P2 and S1P3 were established by immuno-
histochemistry. Cytoplasmic and nuclear SK1 expression was
associated with shorter time to recurrence on tamoxifen (recur-
rence time) (p = 0.022 and p = 0.016, respectively) and high mem-
brane S1P1 expression was also associated with shorter time to
recurrence (p = 0.008). High cytoplasmic S1P1 and S1P3 expres-
sion were associated with shorter disease specific survival
(p = 0.036 and p = 0.019). Those patients with tumours that
expressed high levels of both cytoplasmic SK1 and ERK-1/2
had significantly shorter recurrence time than those that
expressed low levels of cytoplasmic SK1 and cytoplasmic ERK-
1/2 (p = 0.00008), with a difference in recurrence time of
10.5 years. Similarly, high cytoplasmic S1P1 and cytoplasmic
ERK-1/2 expression (p = 0.004) and high cytoplasmic S1P3 expres-
sion and cytoplasmic ERK-1/2 expression (p = 0.004), were associ-
ated with shorter recurrence time. These results support a
model in which the interaction between SK1, S1P1 and/or S1P3
and ERK-1/2 might drive breast cancer progression and this
therefore warrants further investigation.
doi:10.1016/j.ejcsup.2010.06.057
O-57 SCREEN DETECTED DCIS IN THE EAST MIDLANDS REGION:
COMPARISONS IN TREATMENT AND OUTCOME OVER TIME
(1988–2003)
J.A. Reed a, A. Murphy a, G. Comerie a, D.M. Sibbering b. aEast
Midlands Quality Assurance (QA) Reference Centre, Nottingham,
UK. bRoyal Derby Hospital, Derby, UK
A retrospective study was carried out comparing three cohorts
of consecutive patients diagnosed with DCIS via the NHSBSP in
the East Midlands region. Diagnostic, treatment and follow-up
outcome data was collected by individual patient case notes
review, and where necessary by contacting general practitioners.
Kaplan–Meier survival analysis was performed using SPSS.
Histological excision margins were increasingly clear over
time 88% (88/93), 91.5% (94/97) and 98% (00/03). The overall local
recurrence free survival rate was identical for both earlier periods
with 92% at 5 years but improved to 96.1% over 2000/03. 40–56% of
all local recurrences were invasive; 13/23 (88/93), 14/26 (94/97),
and 8/21 (00/03). Use of tamoxifen within the three cohorts was
similar (44–46%) and made no significant difference to rates of
local or contralateral recurrence free survival. Significant differ-
ences in local recurrence rates by operation type were observed
(see Table 1).
Conclusion: Local recurrence rates after breast conserving sur-
gery for screen detected DCIS have reduced over time. This is
likely to be related to higher rates of non-operative diagnosis,
combined with improved histological assessment (grading and
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